Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies. The ...

Polaris Global Equity Strategy highlighted stocks like Gilead Sciences, Inc. (NASDAQ:GILD), in the third quarter 2024 investor letter. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical ...

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%. Elsewhere ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January, alarming community activists who worry the move will ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively ...

For 14 years, scientists have been growing a tree akin to the Judean balsam — the source of the balm of Gilead — but with no modern counterpart. For 14 years, scientists have been growing a ...